RECHERCHE :   Cancers urologiques
Filtrage ? Le champ de filtrage permet de trier les études comportant le mot saisie. La recherche du mot se fait uniquement dans le contenu texte affiché à l'écran.
ETUDE PHASE SITE
MK3475-676: A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette- Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) that is Persistent or Recurrent Following BCG Induction
High risk bladder cancer
III
HUG
INCA 33890-101: A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
Part 1a: Histologically or cytologically confirmed advanced or metastatic solid tumors as follows: BC (pure small-cell carcinoma, pure adenocarcinoma, and pure squamous cell carcinoma are exlucded) - CESC - ESCA - GC - GEJ - Mel - MPM - NSCLC (mixed small-cell and non-small cell lung cancer histology is exlcluded - tumors should not exhibit mutations in EFGR, ALK, ROS1, BRAF) - OC (Sertoli-Leydic or germ cell cancers are excluded) - RCC - SCCHN (Carcinoma of the nasopharynx, salivary gland, or nonsquamous histologies are excluded) - TNBC - PAAD - CRC. Part1b: same as part 1a, plus dMMR/MSI-H CRC and MSS-CRC
I
CHUV
20180146 Phase 1 Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer
cancer de la prostate métastatique résistant à la castration
I
CHUV
SAKK 96/12: Prevention of Symptomatic Skeletal Events with Denosumab Administered every 4 Weeks versus every 12 Weeks – A Non-Inferiority Phase III Trial
Métastases osseuses dans le cancer de la prostate ou du sein
III
CHUV, HUG
SAKK06/19: Intravesical recombinant BCG followed by perioperative chemo-immunotherapy for patients with muscle-invasive bladder cancer (MIBC). A multicenter, single-arm phase II trial
muscle-invasive bladder cancer
II
HUG